Reports
Reports
Analysts’ Viewpoint
Lung disease therapeutics, such as drugs, are used to treat various lung diseases. High incidence and prevalence of Chronic Obstructive Pulmonary Disease (COPD) and rise in awareness programs are driving the global lung disease therapeutics market. Ongoing research & development activities and launch of products for the treatment of COPD are fueling market expansion. Advancements in technology, such as development of biologic therapies, are expected to augment market progress in the near future.
Development of new approaches in therapeutic agent delivery, vaccine development, and nanotechnology-based medical detections are likely to present lucrative opportunities to market players. Companies are focusing on developing new drugs and treatments to improve treatment options for patients with lung disease.
Lung disease therapeutics include a range of drugs and treatments used to manage various lung conditions, including asthma, COPD, lung cancer, and idiopathic pulmonary fibrosis (IPF). The market is driven by factors such as rise in aging population, increase in rate of smoking, growth in air pollution, and surge in awareness about lung diseases.
Some respiratory diseases are acute, such as an infection, and improve with treatment. Other diseases are chronic and must be managed. Chronic respiratory conditions can be caused by various lung diseases. Millions of people in the U.S. suffer from chronic respiratory diseases. Lung diseases are classified into specific conditions; hence, it is difficult to estimate how many people suffer from them.
Asthma is the largest segment of the lung disease therapeutics market, due to its high prevalence and the need for ongoing treatment and management. Asthma affects 24.8 million people in the U.S., including 5.5 million children, and is responsible for millions of emergency department visits and tens of billions of dollars in healthcare costs each year.
Increase in prevalence of lung cancer is a key driver of lung disease therapeutics market growth. It is the leading cause of cancer-related deaths globally, with a projected 1.8 million deaths per year. Incidence of the disease is expected to rise in the next few years. Development of new treatments, such as immunotherapies and targeted therapies, has improved the survival rate and management of lung cancer patients.
Lung cancer is the second most common cancer in both men and women in the U.S., with an estimated 228,820 new cases and 135,720 deaths in 2021. The five-year survival rate for lung cancer is 18%, which is lower than many other types of cancer.
Increase in adoption of screening and early detection methods are expected to contribute to market growth in the next few years. Rise in sophistication in treatment and management of lung cancer is also anticipated to augment market expansion.
Increase in incidence of COPD and rich clinical trial pipeline for new treatments are projected to boost lung disease therapeutics market size. COPD is a major public health concern due to high prevalence and significant impact on quality of life and mortality. Development of new treatments, such as biologics and targeted therapies, is estimated to improve the management of COPD and other lung diseases, leading to an increase in demand for these products. Additionally, the market is expected to benefit from the development of new indications for existing therapies and introduction of new combination therapies.
Leading COPD companies, such as Sanofi, United Therapeutics Corporation, AstraZeneca, Verona Pharma plc, Novartis, Genentech, and Vertex Pharmaceuticals, are focusing on developing new molecules. In September 2021, Renovion and the COPD Foundation announced a new partnership to accelerate the development of a novel therapy for the treatment of excessive airway mucus and inflammation in people with COPD and non-cystic fibrosis (CF) bronchiectasis.
In terms of disease type, the asthma segment accounted for significant global lung disease therapeutics market share in 2021. Asthma is a chronic lung disease that affects the airways, making it difficult to breathe. It is characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, and shortness of breath.
High prevalence and the need for ongoing treatment & management can be ascribed to the large market share of the segment. Different types of medication, including inhaled corticosteroids, beta-agonists, and leukotriene modifiers, are used to manage asthma symptoms and prevent exacerbations.
Based on drug class, the corticosteroids segment led the global lung disease therapeutics market in 2021. Corticosteroids are a class of drugs commonly used to treat lung diseases such as asthma and COPD. These drugs reduce inflammation in the airways, which helps improve breathing.
High effectiveness can be ascribed to the corticosteroids segment's significant share of the lung disease therapeutics market. These drugs are widely used in the treatment of various lung diseases and have been proven to be safe and effective. Therefore, they are often prescribed as first-line therapy for several lung diseases.
The bronchodilators segment held the second-largest share of the market in 2021. Bronchodilator is a type of medication that makes breathing easier. It relaxes the muscles in the lungs and widens the airways. This drug class is used to treat long-term conditions such as asthma and COPD.
In terms of distribution channel, the hospital pharmacies segment dominated the global lung disease therapeutics industry in 2021. Hospital pharmacies are responsible for supplying and dispensing medications to inpatients. Thus, they play a critical role in the management of lung diseases such as COPD and asthma.
Hospital pharmacies have access to a range of medications, including specialized therapeutics for lung diseases. These pharmacies are staffed by trained pharmacists who provide expert advice on medication usage and management. Hospital pharmacies are closely connected to other healthcare professionals such as doctors and nurses, leading to better coordination of care and improved patient outcomes.
Hospital pharmacies have the infrastructure and resources to handle complex medication regimens and manage potential drug interactions or adverse reactions. They also play a key role in monitoring and managing the usage of antibiotics, which are often prescribed for lung infection treatment.
North America accounted for the largest share in 2021. The region has a well-established market and advanced healthcare systems. Market players are making significant investments in research & development activities in the region. Furthermore, high prevalence of lung diseases, such as COPD and asthma, is driving market statistics in North America.
Emerging markets in Asia Pacific and Latin America have less investment in the lung disease therapeutics industry and low prevalence of lung diseases. However, these regions are likely to witness significant market development in the next few years due to improvement in healthcare systems and increase in prevalence of lung diseases.
As per lung disease therapeutics market analysis, Middle East & Africa held small share in 2021. The market in the region is expected to experience robust growth during the forecast period. This can be ascribed to the increase in efforts to improve healthcare infrastructure and rise in patient access to treatment.
Expansion of product portfolio and merger & acquisition are the key strategies adopted by prominent manufacturers in the global lung disease therapeutics market. GSK, AstraZeneca, Boehringer Ingelheim, IQVIA, Novartis, Vertex Pharmaceuticals, F. Hoffman La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, and PharmAkea Therapeutics are the prominent players in the market.
The lung disease therapeutics market report profiles key players based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 76.5 Bn |
|
Forecast (Value) in 2031 |
More than US$ 109.4 Bn |
|
Growth Rate (CAGR) |
3.7% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The industry was valued at US$ 76.5 Bn in 2021.
It is projected to reach more than US$ 109.4 Bn by 2031.
The CAGR is anticipated to be 3.7% from 2022 to 2031.
Rise in prevalence of chronic obstructive pulmonary disease (COPD) & asthma and increase in number of cases of lung cancer.
North America is projected to account for significant share during the forecast period.
GSK, AstraZeneca, IQVIA, Boehringer Ingelheim, Novartis, Vertex Pharmaceuticals, F. Hoffman La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, and PharmAkea Therapeutics.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lung Disease Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Disease Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Drug Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
5.4. Regulatory Scenario by Region/Globally
5.5. COVID-19 Impact Analysis
6. Global Lung Disease Therapeutics Market Analysis and Forecast, by Disease Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2017–2031
6.3.1. Asthma
6.3.2. Chronic Obstructive Pulmonary Disease (COPD)
6.3.3. Lung Cancer
6.3.4. Others
6.4. Market Attractiveness Analysis, by Disease Type
7. Global Lung Disease Therapeutics Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2017–2031
7.3.1. Corticosteroids
7.3.2. Bronchodilator Medications
7.3.3. Mucolytics
7.3.4. Antimicrobial Medications
7.3.5. Others
7.4. Market Attractiveness Analysis, by Drug Class
8. Global Lung Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Lung Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Lung Disease Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Disease Type, 2017–2031
10.2.1. Asthma
10.2.2. Chronic Obstructive Pulmonary Disease (COPD)
10.2.3. Lung Cancer
10.2.4. Others
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Corticosteroids
10.3.2. Bronchodilator Medications
10.3.3. Mucolytics
10.3.4. Antimicrobial Medications
10.3.5. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Disease Type
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Lung Disease Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease Type, 2017–2031
11.2.1. Asthma
11.2.2. Chronic Obstructive Pulmonary Disease (COPD)
11.2.3. Lung Cancer
11.2.4. Others
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Corticosteroids
11.3.2. Bronchodilator Medications
11.3.3. Mucolytics
11.3.4. Antimicrobial Medications
11.3.5. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Disease Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Lung Disease Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2017–2031
12.2.1. Asthma
12.2.2. Chronic Obstructive Pulmonary Disease (COPD)
12.2.3. Lung Cancer
12.2.4. Others
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Corticosteroids
12.3.2. Bronchodilator Medications
12.3.3. Mucolytics
12.3.4. Antimicrobial Medications
12.3.5. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Disease Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Lung Disease Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2017–2031
13.2.1. Asthma
13.2.2. Chronic Obstructive Pulmonary Disease (COPD)
13.2.3. Lung Cancer
13.2.4. Others
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Corticosteroids
13.3.2. Bronchodilator Medications
13.3.3. Mucolytics
13.3.4. Antimicrobial Medications
13.3.5. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Disease Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Lung Disease Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2017–2031
14.2.1. Asthma
14.2.2. Chronic Obstructive Pulmonary Disease (COPD)
14.2.3. Lung Cancer
14.2.4. Others
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Corticosteroids
14.3.2. Bronchodilator Medications
14.3.3. Mucolytics
14.3.4. Antimicrobial Medications
14.3.5. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. Market Attractiveness Analysis
14.6.1. By Disease Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. GSK
15.3.1.1. Company Overview
15.3.1.2. Disease Type Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview
15.3.2.2. Disease Type Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Boehringer Ingelheim
15.3.3.1. Company Overview
15.3.3.2. Disease Type Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Novartis
15.3.4.1. Company Overview
15.3.4.2. Disease Type Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Vertex Pharmaceuticals
15.3.5.1. Company Overview
15.3.5.2. Disease Type Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffman La Roche
15.3.6.1. Company Overview
15.3.6.2. Disease Type Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Teva Pharmaceuticals
15.3.7.1. Company Overview
15.3.7.2. Disease Type Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Cipla
15.3.8.1. Company Overview
15.3.8.2. Disease Type Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Liminal Biosciences
15.3.9.1. Company Overview
15.3.9.2. Disease Type Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Fibrogen
15.3.10.1. Company Overview
15.3.10.2. Disease Type Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. PharmAkea Therapeutics
15.3.11.1. Company Overview
15.3.11.2. Disease Type Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. IQVIA
15.3.12.1. Company Overview
15.3.12.2. Disease Type Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
List of Tables
Table 01: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 02: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 03: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 07: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 08: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 11: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 12: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 15: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 16: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 19: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 20: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 23: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 24: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Lung Disease Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
Figure 02: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Disease Type, 2021
Figure 03: Global Lung Disease Therapeutics Market Value Share, by Disease Type, 2021
Figure 04: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Drug Class, 2021
Figure 05: Global Lung Disease Therapeutics Market Value Share, by Drug Class, 2021
Figure 06: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2021
Figure 07: Global Lung Disease Therapeutics Market Value Share, by Distribution Channel, 2021
Figure 08: Global Lung Disease Therapeutics Market Value Share, by Region, 2021
Figure 09: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
Figure 11: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
Figure 12: Global Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 13: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 14: Global Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 15: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 16: Global Lung Disease Therapeutics Market Value Share Analysis, by Region, 2017 and 2031
Figure 17: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2031
Figure 20: North America Lung Disease Therapeutics Market Value Share Analysis, by Country, 2017 and 2031
Figure 21: North America Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
Figure 22: North America Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 23: North America Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 24: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 25: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 26: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 27: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Europe Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 30: Europe Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
Figure 31: Europe Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 32: Europe Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 33: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 34: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 35: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 36: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 38: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 39: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
Figure 40: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 41: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 42: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 43: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 44: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 45: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 47: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 48: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
Figure 49: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 50: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 51: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 52: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 53: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 54: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 56: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 57: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
Figure 58: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 59: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 60: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022–2031
Figure 61: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 62: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Lung Disease Therapeutics Market